Fundraising FoxInterMune
Unicorn exit · $8.3Bacquired by Roche4 known investors
Find your way into InterMune
Sign up to see every warm intro you have to InterMune
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InterMune team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Roche August 2014 · $8.3B ($74.00 per share, all-cash, ~$8.3 billion total) · source ↗
InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
Founders & leadership
Investors · 4
How we know: Ridgeback Capital's portfolio page · Not right? Tell us
How we know: Sanderling Ventures's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
3 people who came through InterMune went on to found or lead other companies.
Frequently asked questions
- What does InterMune do?
- InterMune was a Brisbane, California biotechnology company focused on pulmonology and fibrotic diseases, best known for developing pirfenidone (Esbriet) to treat idiopathic pulmonary fibrosis.
- Who are InterMune's investors?
- InterMune's investors include Ridgeback Capital, Sanderling Ventures, Sofinnova Ventures, New Enterprise Associates (NEA).
- Who acquired InterMune?
- InterMune was acquired by Roche.